Clinical Trial

QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The trial aimed to compare QL1706 combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) versus IC+CCRT alone in High-risk Locoregionally-Advanced Nasopharyngeal Carcinoma (LANPC).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-23.
Trial Details
NCT Number NCT06749899
Lead Sponsor Sun Yat-Sen University Cancer Center
Collaborators: Qilu Pharmaceutical Co., Ltd.
Conditions Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
Enrollment 580 participants
Start Date 2025-05-04
Primary Completion 2028-12-01 (estimated)
Study Completion 2030-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-05-22